Finance

Beta
Lists
CRL:NYSE
Charles River Lbrtrs ntrntl Inc
224,35 US$
-2,10%
(-4,81) 1D
224,35 US$
0,00% (0,00)
After hours
Closed: 17 ივლ, 16:00:05 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRL...
Open
224,94 US$
High
228,53 US$
Low
222,67 US$
Mkt. cap
10,81 მლრდ.
Avg. vol.
845,31 ათ.
Volume
710,19 ათ.
52-wk high
237,86 US$
52-wk low
144,26 US$
EPS
-3,76 US$
Beta
1,40
Shares outstanding
48,17 მლნ.
No. of employees
19 ათ.
Open
224,94 US$
High
228,53 US$
Low
222,67 US$
Mkt. cap
10,81 მლრდ.
Avg. vol.
845,31 ათ.
Volume
710,19 ათ.
52-wk high
237,86 US$
52-wk low
144,26 US$
EPS
-3,76 US$
Beta
1,40
Shares outstanding
48,17 მლნ.
No. of employees
19 ათ.
News stories
From sources across the web
Profile
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients. Charles River Laboratories is considered one of the largest CROs globally, known for its role in toxicology studies, animal research models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of laboratory animals, including dogs, primates, and horseshoe crabs. As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL. Wikipedia
About Charles River Lbrtrs ntrntl Inc
CEOჯეიმზ სი ფოსტერ
Employees19 ათ.
Founded1947
HeadquartersWilmington, მასაჩუსეტსი, ამერიკის შეერთებული შტატები
SectorHealth care
Websitecriver.com
Analyst ratings
Based on 12 analysts giving stock ratings to CRL in the past 3 months
Strong buy
Buy
11
Hold
1
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for CRL in the last 3 months.
Highest
Current 224,35 US$
265,00 US$ (+18,12%)
Average
230,20 US$ (+2,61%)
Lowest
213,00 US$ (-5,06%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ann Hynes
Mizuho Securities
Hold
Maintained
230,00 US$
+2,5%
07/13/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Reiterated
260,00 US$
+15,9%
07/09/2026
Ryan Halsted
RBC Capital
Buy
Maintained
215,00 US$
-4,2%
07/08/2026
Patrick B Donnelly
Citi
Buy
Maintained
265,00 US$
+18,1%
07/08/2026
Luke Sergott
Barclays
Buy
Maintained
220,00 US$
-1,9%
06/08/2026
Michael Ryskin
Bank of America Securities
Buy
Maintained
-
-
06/05/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
235,00 US$
+4,7%
06/04/2026
Max Smock
William Blair
Buy
Maintained
-
-
06/02/2026
Michael Luo CFA
CLSA
Buy
Upgraded
219,00 US$
-2,4%
05/29/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
220,00 US$
-1,9%
05/08/2026
David Windley
Jefferies
Buy
Maintained
225,00 US$
+0,3%
05/08/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
213,00 US$
-5,1%
05/08/2026
Charles Weston
RBC Capital
Buy
Initiated
215,00 US$
-4,2%
04/13/2026
Casey Woodring
J.P. Morgan
Hold
Reiterated
160,00 US$
-28,7%
04/13/2026
Dan Leonard
UBS
Hold
Maintained
175,00 US$
-22%
02/25/2026
Last report
7 მაი. 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
2,06 US$ / 1,95 US$
+5,42%beat
Revenue / Est. (USD)
995,83 მლნ. / 979,47 მლნ.
+1,67%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
ივნ. 2025
სექ. 2025
დეკ. 2025
მარ. 2026
Revenue
1,03 მლრდ.
1,00 მლრდ.
994,23 მლნ.
995,83 მლნ.
Cost of goods sold
648,60 მლნ.
652,72 მლნ.
665,36 მლნ.
672,79 მლნ.
Cost of revenue
648,60 მლნ.
652,72 მლნ.
665,36 მლნ.
672,79 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
185,82 მლნ.
173,64 მლნ.
192,02 მლნ.
149,12 მლნ.
Operating expense
211,51 მლნ.
201,05 მლნ.
284,04 მლნ.
164,46 მლნ.
Total operating expenses
860,10 მლნ.
853,77 მლნ.
949,40 მლნ.
837,25 მლნ.
Operating income
172,03 მლნ.
151,08 მლნ.
44,83 მლნ.
158,58 მლნ.
Other non operating income
154,00 ათ.
-22,62 მლნ.
27,72 მლნ.
-123,11 მლნ.
EBT including unusual items
71,42 მლნ.
87,20 მლნ.
-294,10 მლნ.
-29,94 მლნ.
EBT excluding unusual items
143,32 მლნ.
104,48 მლნ.
35,18 მლნ.
8,62 მლნ.
Income tax expense
18,72 მლნ.
31,64 მლნ.
-17,81 მლნ.
-15,14 მლნ.
Effective tax rate
26,22%
36,29%
6,06%
50,56%
Other operating expenses
-
-
-
-
Net income
52,33 მლნ.
54,42 მლნ.
-276,56 მლნ.
-14,84 მლნ.
Net profit margin
5,07%
5,42%
-27,82%
-1,49%
Earnings per share
3,12
2,43
2,39
2,06
Interest and investment income
1,10 მლნ.
1,42 მლნ.
1,02 მლნ.
1,03 მლნ.
Interest expense
-29,97 მლნ.
-25,40 მლნ.
-23,78 მლნ.
-26,74 მლნ.
Net interest expenses
-28,87 მლნ.
-23,98 მლნ.
-22,76 მლნ.
-25,71 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
327,04 მლნ.
165,25 მლნ.
169,61 მლნ.
225,73 მლნ.
Gain or loss from assets sale
-
-
-
117,98 მლნ.
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer